Previous studies in adults with SMA have found no difference in either NFL or NFH in patients pre- or post-treatment with nusinersen, an antisense oligonucleotide that alters SMN2 pre-mRNA splicing [48]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.